business / news / / Benzinga
Pfizer shares were down 2% at $27.37 at the time of publication on Tuesday.
A potential 100% tariff on drugmakers without pricing deals could be announced as soon as Thursday.
KEY POINTS
- Pfizer will stop monitoring participants for COVID-19 symptoms in its vaccine trial after April 3.
- CDC's pause on diagnostic testing for 27 diseases complicates near-term COVID vaccine demand visibility for Pfizer.
- Section 232 national-security investigation is cited as the basis for possible new drug tariffs affecting Pfizer.
- Pfizer's next earnings report is expected May 5, with EPS estimated at 74 cents, down year-over-year.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →